Pancreastatin:: Multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism

被引:71
作者
O'Connor, DT
Cadman, PE
Smiley, C
Salem, RM
Rao, FW
Smith, J
Funk, SD
Mahata, SK
Mahata, M
Wen, G
Taupenot, L
Gonzalez-Yanes, C
Harper, KL
Henry, RR
Sanchez-Margalet, V
机构
[1] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Dept Med, La Jolla, CA 92161 USA
[2] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Dept Pharmacol, La Jolla, CA 92161 USA
[3] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Ctr Genet Mol, La Jolla, CA 92161 USA
[4] Univ Seville, Fac Med, Virgen Macarena Hosp, Seville, Spain
关键词
D O I
10.1210/jc.2005-0408
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: The chromogranin A (CHGA) fragment pancreastatin (human CHGA250-301) impairs glucose metabolism, but the role of human pancreastatin in vivo remains unexplored. Methods: We studied brachial arterial infusion of pancreastatin (CHGA(273-301)-amide at similar to 200 nM) on forearm metabolism of glucose, free fatty acids, and amino acids. Plasma pancreastatin was measured in obesity or type 2 diabetes. Systematic discovery of amino acid variation was performed, and the potency of one variant in the active carboxyl terminus (Gly297Ser) was tested. Results: Pancreastatin decreased glucose uptake by approximately 48-50%; the lack of change in forearm plasma flow indicated a metabolic, rather than hemodynamic, mechanism. A control CHGA peptide ( catestatin, CHGA(352-372)) did not affect glucose. Insulin increased glucose uptake, but pancreastatin did not antagonize this action. Pancreastatin increased spillover of free fatty acids by about 4.5- to 6.4-fold, but not spillover of amino acids. Insulin diminished spillover of both free fatty acids and amino acids, but these actions were not reversed by pancreastatin. Plasma pancreastatin was elevated approximately 3.7-fold in diabetes, but was unchanged during weight loss. Proteolytic cleavage sites for pancreastatin in vivo were documented by matrix-assisted laser desorption ionization/time of flight mass spectrometry. Three pancreastatin variants were discovered: Arg253Trp, Ala256Gly, and Gly297Ser. The Gly297Ser variant had unexpectedly increased potency to inhibit glucose uptake. Conclusions: The dysglycemic peptide pancreastatin is specifically and potently active in humans on multiple facets of intermediary metabolism, although it did not antagonize insulin. Pancreastatin is elevated in diabetes, and the variant Gly297Ser had increased potency to inhibit glucose uptake. The importance of human pancreastatin in vivo as well as its natural variants is established.
引用
收藏
页码:5414 / 5425
页数:12
相关论文
共 47 条
  • [1] VASOSTATINS, COMPRISING THE N-TERMINAL DOMAIN OF CHROMOGRANIN-A, SUPPRESS TENSION IN ISOLATED HUMAN BLOOD-VESSEL SEGMENTS
    AARDAL, S
    HELLE, KB
    ELSAYED, S
    REED, RK
    SERCKHANSSEN, G
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 1993, 5 (04) : 405 - 412
  • [2] CHROMOGRANIN-A - POSTTRANSLATIONAL MODIFICATIONS IN SECRETORY GRANULES
    BARBOSA, JA
    GILL, BM
    TAKIYYUDDIN, MA
    OCONNOR, DT
    [J]. ENDOCRINOLOGY, 1991, 128 (01) : 174 - 190
  • [3] Beynon RJ, 1989, PROTEOLYTIC ENZYMES
  • [4] Chromogranin A processing and secretion - Specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway
    Eskeland, NL
    Zhou, A
    Dinh, TQ
    Wu, HJ
    Parmer, RJ
    Mains, RE
    OConnor, DT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (01) : 148 - 156
  • [5] PARASTATIN (PORCINE CHROMOGRANIN-A(347-419), A NOVEL CHROMOGRANIN-A-DERIVED PEPTIDE, INHIBITS PARATHYROID CELL SECRETION
    FASCIOTTO, BH
    TRAUSS, CA
    GREELEY, GH
    COHN, DV
    [J]. ENDOCRINOLOGY, 1993, 133 (02) : 461 - 466
  • [6] Reproducibility of resting peripheral blood flow using strain gauge plethysmography
    Fehling, PC
    Arciero, PJ
    MacPherson, CJ
    Smith, DL
    [J]. INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 1999, 20 (08) : 555 - 559
  • [7] BIOACTIVITY OF SYNTHETIC C-TERMINAL FRAGMENT OF RAT PANCREASTATIN ON ENDOCRINE PANCREAS
    FUNAKOSHI, A
    MIYASAKA, K
    KITANI, K
    TAMAMURA, H
    FUNAKOSHI, S
    YAJIMA, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 158 (03) : 844 - 849
  • [8] ELEVATED PLASMA-LEVELS OF PANCREASTATIN (PST) IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM)
    FUNAKOSHI, A
    TATEISHI, K
    SHINOZAKI, H
    MATSUMOTO, M
    WAKASUGI, H
    [J]. REGULATORY PEPTIDES, 1990, 30 (02) : 159 - 164
  • [9] ISOLATION AND CHARACTERIZATION OF A TUMOR-DERIVED HUMAN PANCREASTATIN-RELATED PROTEIN
    FUNAKOSHI, S
    TAMAMURA, H
    OHTA, M
    YOSHIZAWA, K
    FUNAKOSHI, A
    MIYASAKA, K
    TATEISHI, K
    TATEMOTO, K
    NAKANO, I
    YAJIMA, H
    FUJII, N
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 164 (01) : 141 - 148
  • [10] CHROMOGRANIN-A EPITOPES - CLUES FROM SYNTHETIC PEPTIDES AND PEPTIDE-MAPPING
    GILL, BM
    BARBOSA, JA
    HOGUEANGELETTI, R
    VARKI, N
    OCONNOR, DT
    [J]. NEUROPEPTIDES, 1992, 21 (02) : 105 - 118